Jennifer Southall
Senior Staff Writer at HemOnc Today
Freelance Medical Writer and Editor at Freelance
Medical editor and reporter | All tweets my own @GoHealio @WomeninOnc @HemOncToday
Articles
-
3 weeks ago |
healio.com | Jennifer Southall
Key takeaways: Significantly fewer Hispanic patients received preferred first-line treatment for CLL vs. white patients. Use of preferred first-line treatment also varied by practice type. CHICAGO — Researchers observed inequities in receipt of first-line preferred therapies among a cohort of patients with chronic lymphocytic leukemia, according to results of a retrospective observational study.
-
3 weeks ago |
healio.com | Jennifer Southall
Key takeaways: Patients assigned liso-cel achieved longer median PFS and OS compared with standard of care. ORR was significantly higher with liso-cel vs. standard of care. CHICAGO — Lisocabtagene maraleucel significantly improved responses rates and survival outcomes among patients with relapsed or refractory chronic lymphocytic leukemia, according to findings presented at ASCO Annual Meeting.
-
3 weeks ago |
healio.com | Jennifer Southall
Key takeaways: Researchers observed significantly worse OS among patients who primarily consumed a proinflammatory diet. Both diet and physical activity influenced OS. CHICAGO — Consuming a noninflammatory diet increased OS for patients with late-stage colon cancer, according to findings from a large, prospective cohort study presented at ASCO Annual Meeting. Of note, regular physical activity appeared to attenuate the association between diet and OS.
-
3 weeks ago |
healio.com | Jennifer Southall
Key takeaways: Survival outcomes with the sacituzumab govitecan combination outweighed outcomes with chemotherapy combination therapy. Researchers reported no new safety concerns with the sacituzumab govitecan combination. CHICAGO — First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy plus pembrolizumab among patients with metastatic triple-negative PD-L1-positive breast cancer.
-
1 month ago |
healio.com | Jennifer Southall
This research highlights two unique topics that are vital in the current oncology research world — the perspective of the caregiver, which is truly understudied, and the indirect costs of cancer treatment. Indirect costs — transportation costs in this case — include costs to patients and family that aren’t directly related to their medical expenses. These may also include lost work and early retirement.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 267
- Tweets
- 244
- DMs Open
- No
RT @HemOncToday: 💥ASCENT-04/KEYNOTE-D19 drops at #ASCO25 Sacituzumab govitecan + pembrolizumab boosts survival 🆚chemo combos in Triple- P…
RT @drsarahsam: First-line Sacituzumab + Pembrolizumab improves PFS in 1st Line TNBC. 🚨🔔‼️ Crossover 80% Sacituzumab Offered! Very few p…
RT @COlazagasti: Incredibly proud of our fellow and rising star @Jani_Chinmay taking the podium to present an oral at #ASCO25 uncovering th…